Published date:Mar 28 2025

Journal Title: Sudan Journal of Medical Sciences

Issue title: Sudan JMS: Volume 20 (2025), Issue No. 1

Pages:50 - 60

DOI: 10.18502/sjms.v20i1.14340

Islam Ahmedislambabiker978@gmail.comDepartment of Clinical Pharmacy, Faculty of Pharmacy, Omdurman Islamic University, Khartoum

Lina Altayeblina.faisal@outlook.comDepartment of Pharmacy Practice, Faculty of Pharmacy, Omdurman Islamic University, Khartoum

Department of Pharmacy Practice

Background: Multimorbidity is linked with poor patient outcomes, polypharmacy, and treatment burden. Treatment burden is the workload needed by patients to manage their multiple chronic conditions. We aimed to assess treatment burden and its predictors in patients with multimorbidity at the internal medicine clinic of the Omdurman Teaching Hospital.

Methods: This was a descriptive, cross-sectional study. Patients were eligible for inclusion if they were aged ≥55 years and had ≥2 self-reported chronic conditions. Treatment burden was measured through the Multimorbidity Treatment Burden Questionnaire (MTBQ). Multivariable logistic regression was used to predict the factors associated with a high treatment burden. SPSS V.26 was used for statistical analysis.

Results: A total of 256 participants were recruited (the median age was 64 years, and 39.1% were men). About 47% of participants had more than three chronic conditions, with hypertension (89.5%) and diabetes (82.0%) being the most common. Eighty-one percent of the participants had a high treatment burden with a median score of 40.4 (28.8–51.9). Arranging appointments (83.7%), seeing several health professionals (83.5%), and collecting prescription medicines (83.2%) were perceived as difficult tasks. Aspects related to treatment (collection of, taking, and paying for medicines) were the most difficult as perceived by participants. Low education (OR = 10.46; CI 3.01–36.39; P = 0.000), living outside Khartoum (OR = 4.24; CI 1.22–14.73; P = 0.023), having more chronic conditions (OR = 1.75; CI 1.03-2.97; P = 0.038), and taking more regular medications (OR = 1.32; CI 1.09–1.61; P = 0.004) were independently associated with high treatment burden.

Conclusion: A high treatment burden was common and was primarily incurred by difficulties in interacting with many healthcare providers and obtaining prescribed medicines. More attention should be given to assessing and supporting patients with multimorbidity to reduce the burden through organized and integrated healthcare services.

Keywords: chronic conditions, multimorbidity, outpatient, polypharmacy, treatment burden How

[1] Johnston, M. C., Crilly, M., Black, C., Prescott, G. J., & Mercer, S. W. (2019). Defining and measuring multimorbidity: A systematic review of systematic reviews. European Journal of Public Health, 29(1), 182–189. https://doi.org/10.1093/eurpub/cky098

[2] Chowdhury, S. R., Chandra Das, D., Sunna, T. C., Beyene, J., & Hossain, A. (2023). Global and regional prevalence of multimorbidity in the adult population in community settings: A systematic review and meta-analysis. EClinicalMedicine, 57, 101860. https://doi.org/10.1016/j.eclinm.2023.101860

[3] Asogwa, O. A., Boateng, D., Marzà-Florensa, A., Peters, S., Levitt, N., van Olmen, J., & Klipstein-Grobusch, K. (2022). Multimorbidity of non-communicable diseases in low-income and middle-income countries: A systematic review and meta-analysis. BMJ Open, 12(1), e049133. https://doi.org/10.1136/bmjopen-2021-049133

[4] Tran, P. B., Kazibwe, J., Nikolaidis, G. F., Linnosmaa, I., Rijken, M., & van Olmen, J. (2022). Costs of multimorbidity: A systematic review and meta-analyses. BMC Medicine, 20(1), 234. https://doi.org/10.1186/s12916-022-02427-9

[5] Al-Mansouri, A., Hamad, A. I., Al-Ali, F. S., Ibrahim, M. I. M., Kheir, N., Al-Ziftawi, N. H., Ibrahim, R. A., AlBakri, M., & Awaisu, A. (2023). Pill-burden and its association with treatment burden among patients with advanced stages of chronic kidney disease. Saudi Pharmaceutical Journal, 31(5), 678– 686. https://doi.org/10.1016/j.jsps.2023.03.008

[6] Kernick, D., Chew-Graham, C. A., & O’Flynn, N. (2017). Clinical assessment and management of multimorbidity: NICE guideline. The British Journal of General Practice, 67(658), 235–236. https://doi.org/10.3399/bjgp17X690857

[7] van Merode, T., van de Ven, K., & van den Akker, M. (2018). Patients with multimorbidity and their treatment burden in different daily life domains: A qualitative study in primary care in the Netherlands and Belgium. Journal of Comorbidity, 8(1), 9–15. https://doi.org/10.15256/joc.2018.8.119

[8] Rosbach, M., & Andersen, J. S. (2017). Patientexperienced burden of treatment in patients with multimorbidity: A systematic review of qualitative data. PLoS One, 12(6), e0179916. https://doi.org/10.1371/journal.pone.0179916

[9] Charani, E., Cunnington, A. J., Yousif, A. H. A., Seed Ahmed, M., Ahmed, A. E. M., Babiker, S., Badri, S., Buytaert, W., Crawford, M. A., Elbashir, M. I., Elhag, K., Elsiddig, K. E., Hakim, N., Johnson, M. R., Miras, A. D., Swar, M. O., Templeton, M. R., & Taylor-Robinson, S. D. (2019). In transition: Current health challenges and priorities in Sudan. BMJ Global Health, 4(4), e001723. https://doi.org/10.1136/bmjgh-2019-001723

[10] Alorini, M., Omar, S., Abubaker, M., & Adam, I. (2023). Multimorbidity in Sudanese women newly diagnosed with breast cancer: A retrospective cross-sectional study. F1000 Research, 12, 89. https://doi.org/10.12688/f1000research.127325.1

[11] Lucero-Prisno, D. E., III, Elhadi, Y. A. M., Modber, M. A. A., Musa, M. B., Mohammed, S. E. E., Hassan, K. F., Dafallah, A., Lin, X., Ahmadi, A., Adeyemi, S., Ekpenyong, A., & Adebisi, Y. A. (2020). Drug shortage crisis in Sudan in times of COVID-19. Public Health in Practice (Oxford, England), 1, 100060. https://doi.org/10.1016/j.puhip.2020.100060

[12] Ebrahim, E. M. A., Ghebrehiwot, L., Abdalgfar, T., & Juni, M. H. (2017). Health care system in Sudan: Review and analysis of strength, weakness, opportunity, and threats (SWOT analysis). Sudan Journal of Medical Sciences, 12(3), 133–150. https://doi.org/10.18502/sjms.v12i3.924

[13] Duncan, P., Murphy, M., Man, M. S., Chaplin, K., Gaunt, D., & Salisbury, C. (2018). Development and validation of the Multimorbidity Treatment Burden Questionnaire (MTBQ). BMJ Open, 8(4), e019413. https://doi.org/10.1136/bmjopen-2017-019413

[14] Ismail, S., Stanley, A., & Jeemon, P. (2022). Prevalence of multimorbidity and associated treatment burden in primary care settings in Kerala: A cross-sectional study in Malappuram District, Kerala, India. Wellcome Open Research, 7, 67. https://doi.org/10.12688/wellcomeopenres.17674.2

[15] Guénette, L., Turcotte, V., Bélanger, L., Blais, L., Sirois, C., Lunghi, C., & Duncan, P. (2023). Multimorbidity Treatment Burden Questionnaire (MTBQ): Translation, cultural adaptation, and validation in French-Canadian. Canadian Journal on Aging, 42(1), 126–134. https://doi.org/10.1017/S0714980822000058

[16] Morris, J. E., Roderick, P. J., Harris, S., Yao, G., Crowe, S., Phillips, D., Duncan, P., & Fraser, S. D. (2021). Treatment burden for patients with multimorbidity: Cross-sectional study with exploration of a single-item measure. The British Journal of General Practice, 71(706), e381–e390. https://doi.org/10.3399/BJGP.2020.0883

[17] Eyowas, F. A., Schneider, M., Alemu, S., & Getahun, F. A. (2023). Experience of living with multimorbidity and health workers perspectives on the organization of health services for people living with multiple chronic conditions in Bahir Dar, northwest Ethiopia: A qualitative study. BMC Health Services Research, 23(1), 232. https://doi.org/10.1186/s12913-023-09250- 9

[18] Roomaney, R. A., van Wyk, B., & Pillay-van Wyk, V. (2022). A systematic method for comparing multimorbidity in national surveys. BMC Research Notes, 15(1), 280. https://doi.org/10.1186/s13104-022- 06164-3

[19] Pedersen, M. H., Duncan, P., Lasgaard, M., Friis, K., Salisbury, C., & Breinholt Larsen, F. (2022). Danish validation of the Multimorbidity Treatment Burden Questionnaire (MTBQ) and findings from a population health survey: A mixed-methods study. BMJ Open, 12(1), e055276. https://doi.org/10.1136/bmjopen-2021-055276

[20] Dou, L., Huang, J., Duncan, P., & Guo, L. (2020). Translation, cultural adaptation and validation of the Chinese Multimorbidity Treatment Burden Questionnaire(C-MTBQ): A study of older hospital patients. Health and Quality of Life Outcomes, 18(1), 194. https://doi.org/10.1186/s12955-020-01395-z

[21] Schulze, J., Breckner, A., Duncan, P., Scherer, M., Pohontsch, N. J., & Lühmann, D. (2022). Adaptation and validation of a German version of the Multimorbidity Treatment Burden Questionnaire. Health and Quality of Life Outcomes, 20(1), 90. https://doi.org/10.1186/s12955-022-01993-z

[22] Basto-Abreu, A., Barrientos-Gutierrez, T., Wade, A. N., Oliveira de Melo, D., Seme ao de Souza, A. S., Nunes, B. P., Perianayagam, A., Tian, M., Yan, L. L., Ghosh, A., & Miranda, J. J. (2022). Multimorbidity matters in low and middle-income countries. Journal of Multimorbidity and Comorbidity, 12, 26335565221106074. https://doi.org/10.1177/26335565221106074

[23] Elhadi, Y. A. M., Ahmed, A., Ghazy, R. M., Salih, E. B., Abdelhamed, O. S., Shaaban, R., Mohamed, H. M. H., Mohamed, A. E., El Dabbah, N. A., & Zaghloul, A. A. Z. (2022). Healthcare utilization with drug acquisition and expenses at the National Health Insurance Fund in Sudan. Healthcare (Basel), 10(4), 630. https://doi.org/10.3390/healthcare10040630